AbbVie pens another T cell engager deal, this time with Xilio
AbbVie and Xilio Therapeutics are partnering to make “masked” T cell engagers, which they hope will be safer than currently available options.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
